Bank predicts Novo sales growth of 25% this year
A Danske Bank analyst has concluded that Novo Nordisk has expanded its production capacity so much that it will enable it to nearly double sales of the weight loss drug Wegovy in 2024.
BY MARKETWIRE
Novo Nordisk also has the prospect of significant growth this year, although the company’s management will probably be relatively conservative when it sets its guidance in its annual report on January 31, Danske Bank concludes in a prelude to the report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA finds no proof that GLP-1 drugs cause suicidal thougts
For subscribers
Novo Nordisk joins genomic data alliance
For subscribers
